<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01721642</url>
  </required_header>
  <id_info>
    <org_study_id>CIP-DP1</org_study_id>
    <nct_id>NCT01721642</nct_id>
  </id_info>
  <brief_title>A Pilot Study to Evaluate the Safety and Efficacy of the Apica Access, Stabilization and Closure (ASC™) Device</brief_title>
  <official_title>A Pilot Study to Evaluate the Safety and Efficacy of the Apica Access, Stabilization and Closure (ASC™) Device During and After Transcatheter Aortic Valve Implantation (TAVI) Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Apica Cardiovascular Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Apica Cardiovascular Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A pilot study to evaluate the safety and efficacy of the Apica Access, Stabilization, and&#xD;
      Closure Device for accessing and closing the left ventricular apex during and after&#xD;
      Transcatheter Aortic Valve Implantation (TAVI) procedures. Follow-up assessment will be made&#xD;
      post-procedure, at 30 days and 90 days as well as longer term follow-up.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Access safety</measure>
    <time_frame>Within 2 hours from initial skin incision</time_frame>
    <description>Observation of no myocardial tearing on entry of the device</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Closure safety</measure>
    <time_frame>Within 2 hours from initial skin incision</time_frame>
    <description>Observation of no acute post-procedural bleeding or pericardial effusion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigational device performance: LV function</measure>
    <time_frame>24 hours, 30 days and 90 days post-procedure</time_frame>
    <description>% LVEF no worse than baseline as assessed by echocardiography</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>Apica Cardiovascular ASC Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Access, stabilisation and closure with the Apica Cardiovascular ASC Device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Apica Cardiovascular ASC Access, Stability and Closure Device</intervention_name>
    <description>Access, stabilisation and closure of trans-apical approach for TAVI</description>
    <arm_group_label>Apica Cardiovascular ASC Device</arm_group_label>
    <other_name>Apica Cardiovascular, ASC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject age ≥ 18 years of age.&#xD;
&#xD;
          -  Subjects will be selected in accordance with the investigating centers standard&#xD;
             operating procedures for TAVI subject selection and treatment. Subjects selected will&#xD;
             meet all of the TAVI inclusion criteria as follows:&#xD;
&#xD;
               -  Subject has Senile degenerative aortic stenosis with echocardiography derived&#xD;
                  criteria: mean gradient &gt; 40 mm Hg or jet velocity &gt; 4.0 m/s or an aortic valve&#xD;
                  area (AVA) of &lt; 0.8 cm2 (or AVA index &lt; 0.5 cm2/m2.&#xD;
&#xD;
               -  Subject is symptomatic due to aortic valve stenosis as demonstrated by NYHA&#xD;
                  Functional Class &gt; II.&#xD;
&#xD;
               -  Additive EuroScore &gt; 9&#xD;
&#xD;
               -  Aortic annulus diameter &gt; 21mm to &lt; 27mm by TEE&#xD;
&#xD;
               -  The subject or the subject's legal representative has been informed of the nature&#xD;
                  of the study, agrees to its provisions and has provided written informed consent.&#xD;
&#xD;
               -  The subject and the treating physician agree that the subject will return for all&#xD;
                  required post-procedure follow-up visits.&#xD;
&#xD;
               -  The subject, after formal consults by a cardiologist and two cardiovascular&#xD;
                  surgeons agreed that medical factors precluding operation, based on a conclusion&#xD;
                  that the probability of death or serious, irreversible morbidity exceeded the&#xD;
                  probability of meaningful improvement. Specifically the probability of death or&#xD;
                  serious, irreversible morbidity exceeded 50%.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects will be selected in accordance with the investigating centers standard operating&#xD;
        procedures for TAVI subject selection and treatment. The following TAVI exclusion criteria&#xD;
        shall apply:&#xD;
&#xD;
          -  Evidence of an acute myocardial infarction &lt; 1 month before the intended treatment&#xD;
&#xD;
          -  Aortic valve is a congenital unicuspid or bicuspid valve; or is non-calcified&#xD;
&#xD;
          -  Mixed aortic valve disease (aortic stenosis and aortic regurgitation with predominant&#xD;
             aortic regurgitation &gt; 3+)&#xD;
&#xD;
          -  Pre-existing prosthetic heart valve in an position, prosthetic ring, or severe&#xD;
             (greater than 3+) mitral insufficiency&#xD;
&#xD;
          -  Blood dyscrasias as defined: Leukopenia, acute anemia, thrombocytopenia, history of&#xD;
             bleeding diathesis or coagulopathy.&#xD;
&#xD;
          -  Untreated clinically significant coronary artery disease requiring revascularization&#xD;
&#xD;
          -  Hemodynamic instability requiring inotropic therapy or mechanical hemodynamic support&#xD;
             devices&#xD;
&#xD;
          -  Need for emergency surgery for any reason&#xD;
&#xD;
          -  Hypertrophic cardiomyopathy with or without obstruction&#xD;
&#xD;
          -  Echocardiographic evidence of intracardiac mass, thrombus or vegetation&#xD;
&#xD;
          -  Active peptic ulcer or upper gastro-intestinal bleeding within the prior 3 months&#xD;
&#xD;
          -  A known hypersensitivity of contraindication to asprin, heparin, ticlopidine (Ticlid),&#xD;
             or clopidogrel (Plavix), or sensitivity to contrast media, which cannot be adequately&#xD;
             pre-medicated&#xD;
&#xD;
          -  Recent (within 6 months) cerebrovascular accident or transient ischemic attack&#xD;
&#xD;
          -  Renal insufficiency and/or end stage renal disease requiring chronic dialysis.&#xD;
&#xD;
          -  Life expectancy &lt; 12 months due to non-cardiac co-morbid conditions.&#xD;
&#xD;
        The following ASC device exclusion criteria shall apply:&#xD;
&#xD;
          -  Subjects with &lt;10mm Left ventricular wall thickness at apical access site&#xD;
&#xD;
          -  LVEF &lt; 30%&#xD;
&#xD;
          -  Subject with previous DOR procedure&#xD;
&#xD;
          -  Subject access site has less than 2 cm squared &quot;fat&quot; free area under visual&#xD;
             observation&#xD;
&#xD;
          -  Subject has known Allergy or hypersensitivity to Titanium&#xD;
&#xD;
          -  Subject requires MR Imaging post procedure&#xD;
&#xD;
          -  Subject is Pregnant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Walther, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kerckhoff Klinik</affiliation>
  </overall_official>
  <verification_date>June 2014</verification_date>
  <study_first_submitted>September 25, 2012</study_first_submitted>
  <study_first_submitted_qc>November 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2012</study_first_posted>
  <last_update_submitted>June 26, 2014</last_update_submitted>
  <last_update_submitted_qc>June 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>access</keyword>
  <keyword>closure</keyword>
  <keyword>trans-apical</keyword>
  <keyword>trans-catheter aortic valve implantation</keyword>
  <keyword>TAVI</keyword>
  <keyword>trans-catheter aortic valve repair</keyword>
  <keyword>TAVR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

